Inside Precision Medicine September 19, 2024
MicroRNAs (miRNAs) in the blood could provide a new way to diagnose mild cognitive impairment and predict progression to dementia years before it is officially diagnosed, two studies suggest.
The findings could lead to greater understanding of the molecular mechanisms underlying the plaques, tangles and brain atrophy that are hallmarks of Alzheimer’s disease, the most common form of dementia in the elderly.
They could also provide clues to the next generation of therapeutic targets and and help lead to screening in a point-of-care setting.
MiRNAs may further represent a less invasive and more cost-effective alternative to measuring β-amyloid (A) and tau (T) proteins and neurodegeneration (N) assessed in brain tissue, through brain imaging and investigations of cerebrospinal fluid and plasma.
...Today's Sponsors
Today's Sponsor